Bench Study Highlights Performance Edge for Bright Uro’s Glean System

According to a recent LinkedIn post from Bright Uro, a head-to-head bench study is described that compares the company’s Glean sensors with traditional air-charged catheters from Laborie in a simulated human bladder model. The post indicates that 30 Glean sensors and 30 traditional catheters were evaluated on response time, bandwidth, maximum error, and linearity.

The post reports that Glean outperformed the traditional catheter across all four metrics, with differences characterized as statistically significant at p < 0.001. It further suggests that Glean delivers equal or better diagnostic performance than traditional catheters while also being preferred by patients over conventional urodynamics. For investors, these claims, if supported in clinical and real-world settings, could enhance Bright Uro’s competitive positioning in the urodynamics market and support premium pricing or faster adoption by clinicians. Stronger diagnostic performance and patient preference may help differentiate the Glean system against established incumbents like Laborie, potentially translating into higher procedure volumes and recurring revenue over time. The reference in the post to a published article may also indicate an effort to build scientific validation, which is often critical for hospital procurement decisions and reimbursement support. Continued publication of comparative performance data and patient-centric outcomes could improve Bright Uro’s prospects for partnerships with healthcare systems and large urology practices, while also signaling maturation of its technology platform to current and prospective investors.